Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 27.71M | 20.16M | 19.47M | 33.40M | 29.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.71M | 20.16M | 19.47M | 33.40M | 29.38M |
| Cost of Revenue | 1.81M | 1.72M | 3.10M | 7.30M | 4.63M |
| Gross Profit | 25.91M | 18.44M | 16.38M | 26.10M | 24.76M |
| SG&A Expenses | 28.59M | 29.67M | 37.83M | 46.01M | 36.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.34M | 77.60M | 90.85M | 103.44M | 110.96M |
| Operating Income | -43.63M | -57.44M | -71.37M | -70.05M | -81.58M |
| Income Before Tax | -41.26M | -57.19M | -76.14M | -81.39M | -73.35M |
| Income Tax Expenses | -271.00K | 128.00K | -80.00K | -643.00K | 1.00K |
| Earnings from Continuing Operations | -40.98M | -57.32M | -76.06M | -80.75M | -73.35M |
| Earnings from Discontinued Operations | -- | 10.61M | -6.53M | -- | -7.40M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.98M | -46.71M | -82.59M | -80.75M | -80.76M |
| EBIT | -43.63M | -57.44M | -71.37M | -70.05M | -81.58M |
| EBITDA | -35.80M | -49.23M | -62.78M | -61.08M | -72.06M |
| EPS Basic | -0.64 | -0.75 | -1.39 | -1.41 | -1.45 |
| Normalized Basic EPS | -0.40 | -0.58 | -0.72 | -0.68 | -0.86 |
| EPS Diluted | -0.64 | -0.75 | -1.39 | -1.42 | -1.45 |
| Normalized Diluted EPS | -0.40 | -0.58 | -0.72 | -0.68 | -0.86 |
| Average Basic Shares Outstanding | 63.97M | 62.09M | 59.56M | 57.08M | 55.63M |
| Average Diluted Shares Outstanding | 63.97M | 62.09M | 59.56M | 57.08M | 55.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |